Condition: Streptococcus Infection · Sponsor: University Hospital, Strasbourg, France
Clindamycin is an antibiotic with several advantages: high oral bioavailability and good bone and joint penetration. In France, it is a recommended drug for other types of Streptococcus spp. osteoarticular infections and can be used as an alternative to amoxicillin for periprosthetic infections, including when implants are retained. The hypothesis of this study is that clindamycin is no less effective than other drugs commonly used to treat periprosthetic Streptococcus spp. infections. The primary objective of this study is to evaluate the success rate of Streptococcus spp. periprosthetic joint infections treated with clindamycin compared to other antibiotic treatments.
This description comes directly from the study's public registry record.
Stéphane KLEIN, MD · 33 3 68 76 52 32 · stephane.klein@chru-strasbourg.fr
Always discuss trial participation with your own doctor first.
| Service de Chirurgie Orthopédique Septique - CHU de Strasbourg - France | Strasbourg, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07335627